Home › Funds › Carlyle Group Inc. › ACET

Carlyle Group Inc. position in ACET

ADICET BIO INC · Health Care

Carlyle Group Inc. reported holding 184,295 shares of ACET (ADICET BIO INC) in its Q3 2026 13F filing — a position valued at US$1.3M, representing 0.02% of its reported portfolio and ranking #8 among its reported holdings. Carlyle Group Inc. has disclosed ACET holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)184.29K sh
Reported value held$1.32M
Portfolio Weight0.02%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Carlyle Group Inc.'s ACET position evolved

Carlyle Group Inc. first disclosed a stake in ACET in Q3 2023 at 2,115,385 shares (US$2.9M). The position peaked in Q1 2024 at 2,948,718 shares, worth US$6.9M. Across 13 filings, Carlyle Group Inc. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 10 time(s). The most recent filing (Q3 2026) shows 184,295 shares valued at US$1.3M. Notable position changes include a 39% increase in Q1 2024 (shares fell 49% over the following quarter), a 94% trim in Q4 2025 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.12M $2.88M New
Q4 2023 2.12M $3.98M Hold
Q1 2024 2.95M $6.90M Add
Q2 2024 2.95M $3.60M Hold
Q3 2024 2.95M $4.25M Hold
Q4 2024 2.95M $2.84M Hold
Q1 2025 2.95M $2.28M Hold
Q2 2025 2.95M $1.80M Hold
Q3 2025 2.95M $2.39M Hold
Q4 2025 184.29K $1.54M Reduce
Q1 2026 184.29K $1.26M Hold
Q2 2026 184.29K $1.59M Hold
Q3 2026 184.29K $1.32M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ACET and 13F data

ACET (ADICET BIO INC) is a Health Care company. 24 other funds we track also report a position in ACET — the largest reported positions include Stonepine Capital Management, LLC (US$2.1M), REGENERON PHARMACEUTICALS, INC. (US$432K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ACET

All ACET fund holders →

FAQ

How long has Carlyle Group Inc. held ACET?

Carlyle Group Inc. has disclosed ACET holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Carlyle Group Inc.'s current position in ACET?

As of Q3 2026, Carlyle Group Inc. holds 184.29K shares of ACET (ADICET BIO INC), valued at $1.32M, representing 0.02% of its reported portfolio and ranking #8.

Has Carlyle Group Inc. been buying or selling ACET?

In the latest 13F filing (Q3 2026), Carlyle Group Inc. held unchanged its position in ACET. The position peaked in Q1 2024 at 2.95M shares.

Which other funds hold ACET?

Other major institutional holders of ACET include Stonepine Capital Management, LLC, REGENERON PHARMACEUTICALS, INC., among 24 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.